A recent study enrolled 69 NSCLC patients harboring MET exon 14 alterations that were treated with crizotinib and reported an ORR of 32% and a median PFS of 7.3 months, suggesting antitumor activity with crizotinib treatment [120]. Here, MET is linked to non-small cell lung carcinoma.